- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Podcast
The Cutaneous Connection: Advancements in Atopic Dermatitis Treatment
Author(s):
In this episode, Raj Chovatiya, MD, PhD, and assistant professor of dermatology and director of the Center for Ecezma and Itch at the Northwestern University Feinberg School of Medicine, discusses the changing field of atopic dermatitis, the importance of JAK inhibitors, and the treatment options he looks forward to.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Christopher Bunick, MD, PhD, Previews RAD 2025: Raising the Bar in Atopic Dermatitis Care
Current Unmet Needs and Emerging Solutions in Atopic Dermatitis Management
Implementation Factors Affecting Ruxolitinib Adoption in Pediatric Dermatology Practice
Regulatory Challenges and Clinical Differentiators for Pediatric Atopic Dermatitis Treatments
Evaluating the Impact of Topical JAK Inhibitors on Pediatric Atopic Dermatitis Guidelines
The Future of Pediatric Atopic Dermatitis Treatment and Emerging Therapies
Future Perspectives: Can Innovative Topical Therapies Like Ruxolitinib Reduce Systemic Treatment Dependency in Pediatric AD?
Treatment Escalation and De-escalation Strategies in Pediatric AD: Positioning Ruxolitinib Cream in Clinical Decision-Making
Benefits of Nonsteroidal Topical JAK Inhibitors for Moderate Pediatric Atopic Dermatitis
Identifying and Addressing Critical Gaps in Pediatric Atopic Dermatitis Treatment with Ruxolitinib Cream
Related Content
